Cargando…

A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers

Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Janzic, Urska, Bidovec-Stojkovic, Urska, Korosec, Peter, Mohorcic, Katja, Mrak, Loredana, Caks, Marina, Ravnik, Maja, Skof, Erik, Rijavec, Matija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301109/
https://www.ncbi.nlm.nih.gov/pubmed/37376406
http://dx.doi.org/10.3390/vaccines11061017
_version_ 1785064734749360128
author Janzic, Urska
Bidovec-Stojkovic, Urska
Korosec, Peter
Mohorcic, Katja
Mrak, Loredana
Caks, Marina
Ravnik, Maja
Skof, Erik
Rijavec, Matija
author_facet Janzic, Urska
Bidovec-Stojkovic, Urska
Korosec, Peter
Mohorcic, Katja
Mrak, Loredana
Caks, Marina
Ravnik, Maja
Skof, Erik
Rijavec, Matija
author_sort Janzic, Urska
collection PubMed
description Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (p < 0.0001). After the booster third dose, anti-SARS-CoV-2 S1 IgG levels were comparable to healthy controls (p = 0.113). There was a decline in Ab levels 3 (p = 0.0003) and 6 months (p < 0.0001) post-third booster dose. No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infection after the third booster dose. Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course.
format Online
Article
Text
id pubmed-10301109
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103011092023-06-29 A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers Janzic, Urska Bidovec-Stojkovic, Urska Korosec, Peter Mohorcic, Katja Mrak, Loredana Caks, Marina Ravnik, Maja Skof, Erik Rijavec, Matija Vaccines (Basel) Article Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (p < 0.0001). After the booster third dose, anti-SARS-CoV-2 S1 IgG levels were comparable to healthy controls (p = 0.113). There was a decline in Ab levels 3 (p = 0.0003) and 6 months (p < 0.0001) post-third booster dose. No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infection after the third booster dose. Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course. MDPI 2023-05-23 /pmc/articles/PMC10301109/ /pubmed/37376406 http://dx.doi.org/10.3390/vaccines11061017 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Janzic, Urska
Bidovec-Stojkovic, Urska
Korosec, Peter
Mohorcic, Katja
Mrak, Loredana
Caks, Marina
Ravnik, Maja
Skof, Erik
Rijavec, Matija
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
title A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
title_full A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
title_fullStr A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
title_full_unstemmed A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
title_short A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
title_sort three-dose mrna covid-19 vaccine regime produces both suitable immunogenicity and satisfactory efficacy in patients with solid cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301109/
https://www.ncbi.nlm.nih.gov/pubmed/37376406
http://dx.doi.org/10.3390/vaccines11061017
work_keys_str_mv AT janzicurska athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT bidovecstojkovicurska athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT korosecpeter athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT mohorcickatja athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT mrakloredana athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT caksmarina athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT ravnikmaja athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT skoferik athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT rijavecmatija athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT janzicurska threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT bidovecstojkovicurska threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT korosecpeter threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT mohorcickatja threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT mrakloredana threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT caksmarina threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT ravnikmaja threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT skoferik threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers
AT rijavecmatija threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers